SARS-CoV2 InfectionNCT04903132
Cellular Senescence and COVID-19 Long-Hauler Syndrome
An observational study of SARS-CoV2 Infection, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- SARS-CoV2 Infection
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2021to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Longhauler's Cohort: Patients must be at least 18 years or older, have a positive PCR or antibody test within six months, and report any ongoing symptoms associated with Post-COVID or Long-Haulers Syndrome. Control Cohort: Patients must be at least 18 years or older, have not had a known case of COVID-19 or Longhauler's syndrome. COVID Control Cohort: Patients must be at least 18 years or older and have had COVID-19 but no known Longhauler's syndrome.
Who may be able to join
- Ability to give informed consent or LAR.
- At least 18 years old.
- Ability of subject or LAR to read and speak the English language.
- Positive PCR or antibody test within 12 months of initial study visit.
- Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.
- Ability to give informed consent
Show all 12Show fewer
- At least 18 years old
- Ability of subject to read and speak the English language
- Ability to give informed consent.
- At least 18 years old.
- Ability of subject to read and speak the English language.
- Known case of COVID-19.
Who cannot join
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
- Control Cohort -
- Known case of COVID-19.
Show all 16Show fewer
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
- COVID-19 Control Cohort
- Known Longhauler's syndrome/Post-COVID
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
About this study
Official title: Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
Read the detailed description
Assays for cellular senescence markers, SASP factors, inflammatory mediators, pro-fibrotic factors, and auto-antibodies in blood and urine will be conducted in patients who provide informed consent. Data will be related to subject age, date of COVID-19 infection, severity of that infection, current Long-Hauler Syndrome symptoms), physical examination findings, underlying conditions, and laboratory data. To understand if an association between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than controls in this pilot study.
- Conditions
- SARS-CoV2 Infection
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Longhauler's Syndrome Cohort | Subject's with longhaulers | |
| Control Cohort | Control cohort will not have had a known case of COVID-19 or Longhauler's syndrome | |
| COVID Control Cohort | Subjects who have had COVID-19 but no known Longhauler's syndrome |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors
If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2021
- Study start1 Mar 2021
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV2 InfectionStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ryan T. Hurt, M.D., Ph.D., Mayo Clinic
- Investigators
- Ryan T. Hurt, MD, PhD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04903132
- Sponsor's protocol ID
- 20-011877
- Status last verified
- Jul 2026
- First submitted
- 24 May 2021
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome
- ClinicalTrials.gov ID
- NCT04903132
- Acronym / sponsor ID
- 20-011877
- Conditions
- SARS-CoV2 Infection
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 1 Mar 2021 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 26 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.
Detailed description
Assays for cellular senescence markers, SASP factors, inflammatory mediators, pro-fibrotic factors, and auto-antibodies in blood and urine will be conducted in patients who provide informed consent. Data will be related to subject age, date of COVID-19 infection, severity of that infection, current Long-Hauler Syndrome symptoms), physical examination findings, underlying conditions, and laboratory data. To understand if an association between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than controls in this pilot study.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Longhauler's Syndrome Cohort | – | –Subject's with longhaulers |
| Control Cohort | – | –Control cohort will not have had a known case of COVID-19 or Longhauler's syndrome |
| COVID Control Cohort | – | –Subjects who have had COVID-19 but no known Longhauler's syndrome |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Longhauler's Cohort: Patients must be at least 18 years or older, have a positive PCR or antibody test within six months, and report any ongoing symptoms associated with Post-COVID or Long-Haulers Syndrome. Control Cohort: Patients must be at least 18 years or older, have not had a known case of COVID-19 or Longhauler's syndrome. COVID Control Cohort: Patients must be at least 18 years or older and have had COVID-19 but no known Longhauler's syndrome.
Key inclusion criteria (12 listed)
- Ability to give informed consent or LAR.
- At least 18 years old.
- Ability of subject or LAR to read and speak the English language.
- Positive PCR or antibody test within 12 months of initial study visit.
- Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.
Key exclusion criteria (16 listed)
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
- Control Cohort -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors
Time frame: 6 months
If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for SARS-CoV2 Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ryan T. Hurt, MD, PhD principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SARS-CoV2 Infection, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.